课题基金 / 基金详情

First-in-Class Small-molecule Inhibitors Selectively Targeting the DNA-binding Domain of Human Androgen Receptor and Its Splice Variants for the Treatment of Resistant Prostate Cancer

First-in-Class Small-molecule Inhibitors Selectively Targeting the DNA-binding Domain of Human Androgen Receptor and Its Splice Variants for the Treatment of Resistant Prostate Cancer
选择性靶向人雄激素受体及其剪接变体的 DNA 结合域的一流小分子抑制剂,用于治疗耐药性前列腺癌
批准号:
308059
负责人:
Cherkasov Artem
金额:
$10.93万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-02-01 至 2015-02-01

项目摘要

项目成果

Cherkasov Artem的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prostate cancer is the most commonly diagnosed non-skin cancer in Canadian men and one of the leading causes of cancer-related death. If diagnosed early, when still confined to the prostate, it is frequently curable by surgery or radiotherapy. Treatment f
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Computer-aided discovery of synergistic drug combinations with Remdevisir for COVID-19 through mechanism-based drug repurposing and combinatorial organoid screening.
  • 批准号:
    429444
  • 项目类别:
    Operating Grants
  • 资助金额:
    $153.65万
  • 财政年份:
    2020
  • 负责人:
    Cherkasov Artem
  • 依托单位:
Sex as a Biological Variable Supplement - Augmented Discovery of Potential Inhibitors of SARS-CoV-2 3CL Protease
  • 批准号:
    424703
  • 项目类别:
    Operating Grants
  • 资助金额:
    $3.64万
  • 财政年份:
    2020
  • 负责人:
    Cherkasov Artem
  • 依托单位:
海外基金